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Exosomes are vesicles secreted to the extracellular environment through fusion with the
plasma membrane of specific endosomes called multivesicular bodies (MVB) and mediate
cell-to-cell communication in many biological processes. Posttranslational modifications are
involved in the sorting of specific proteins into exosomes. Here we identify ISGylation as a
ubiquitin-like modification that controls exosome release. ISGylation induction decreases
MVB numbers and impairs exosome secretion. Using ISG15-knockout mice and mice
expressing the enzymatically inactive form of the de-ISGylase USP18, we demonstrate in vitro
and in vivo that ISG15 conjugation regulates exosome secretion. ISG15 conjugation triggers
MVB co-localization with lysosomes and promotes the aggregation and degradation of MVB
proteins. Accordingly, inhibition of lysosomal function or autophagy restores exosome
secretion. Specifically, ISGylation of the MVB protein TSG101 induces its aggregation and
degradation, being sufficient to impair exosome secretion. These results identify ISGylation as
a novel ubiquitin-like modifier in the control of exosome production.
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E
xosomes are vesicles secreted to the extracellular
environment by most cell types. They are key mediators
of cell-to-cell communication in many different contexts,
including the immune response1,2 and tumour progression3,4.
Exosomes originate in endosomal compartments called
multivesicular bodies (MVBs), which are late endosomes
containing multiple intraluminal vesicles (ILVs) formed by the
invagination of the endosomal membrane. When MVBs fuse with
the plasma membrane, ILVs are released as exosomes5.
Alternatively, MVBs can fuse with the lysosomal compartment,
resulting in degradation of their content.
Exosome composition is not a mere copy of cytosolic content;
rather, specific proteins and nucleic acids are selectively sorted
into exosomes. The amount and content of exosomes can
moreover change in response to different stimuli6,7. Such changes
in exosome composition determine the final outcome of
exosome-mediated communication8,9.
The mechanisms that control exosome composition and
content are still not well understood10. Posttranslational
modifications such as ubiquitination may play an important
role in the sorting of proteins into exosomes11–13. The endosomal
sorting complex required for transport (ESCRT) recognizes
ubiquitinated proteins and sorts them into ILVs14. The ESCRT
complex is essential for the sorting of proteins such as epidermal
growth factor receptor into MVBs that are degraded through
fusion with lysosomes15, but is also involved in the regulation of
exosome composition and secretion16,17. Another ubiquitin-like
protein (UBL) that can modify exosomal proteins is SUMO,
whose conjugation to hnRNPA2B1 is essential for the sorting of
microRNAs into exosomes18, and enhances the secretion of
a-synuclein into extracellular vesicles (EVs) in an ESCRT-
dependent manner19.
ISG15 is an interferon (IFN)-a/b-induced UBL20, which exerts
its functions in two distinct states: as a free molecule (intracellular
and extracellular)21 or conjugated to target proteins
(ISGylation)22,23. Analogous to ubiquitin, ISG15 conjugation is
mediated by the consecutive action of an E1-activating enzyme
(Ube1L), an E2-conjugating enzyme (UbCH8) and E3 ligases
(mHERC6/hHERC5)24–26, and counteracted by the specific
isopeptidase USP18 (ref. 27). ISGylation was shown to occur in
a co-translational process favouring modification of viral proteins
in infected cells, which, in turn, interferes with virus assembly or
function28–30. Furthermore, cellular proteins involved in antiviral
defense or export of viral particles have been shown to be
ISGylated, supporting the antiviral function of ISG15 (ref. 28).
Studies in mice have demonstrated a role for ISG15 in antiviral
immunity. Hence, mice lacking ISG15 exhibit a higher
susceptibility to several pathogens including virus31 and
bacteria32, and this is reverted in USP18-mutant mice, in which
high levels of ISG15 conjugation are observed33. However,
human ISG15 seems to have critical immune functions but
not in antiviral immunity; unlike mice, ISG15 deficiency
increased viral resistance in humans34. Specifically, free
extracellular human ISG15 is important in IFN-g-dependent
anti-mycobacterial immunity21, whereas free intracellular ISG15
is involved in USP18-mediated downregulation of IFN-a/b
signalling35.
ISG15 expression blocks the process of virus-budding by
different mechanisms such as the blockage of ESCRT machinery
in HIV-infected cells36, or in the case of Ebola and other
enveloped virus infections, inhibiting the Nedd4 E3 ubiquitin
ligase37. Interestingly, exosomes and viruses share many features,
and some viruses have been shown to exploit exosome and
microvesicle secretion pathways38,39. In addition, exosomes
are enriched in ISGylation targets, such as TSG101 (ref. 40)
and heat-shock proteins41.
Here we show that IFN-I inhibits exosome secretion by inducing
protein ISGylation. We demonstrate that the ISGylation of the
MVB protein TSG101 induces its aggregation and degradation,
and this is sufficient for impairing exosome secretion. Moreover,
the ISGylation-induced defect in exosome secretion is rescued on
inhibition of lysosomal function or autophagy.
Results
ISGylation inhibits exosome secretion. To analyse the role of
ISGylation on exosome production, we first treated Jurkat T cells
with IFN-I, to induce ISG15 expression and conjugation
(Supplementary Fig. 1A), and purified the secreted EVs from
their culture supernatants by a serial ultracentrifugation protocol.
IFN-I treatment inhibited the secretion of the classical exosome
markers CD63, TSG101 and CD81 in the purified EVs (Fig. 1a).
A concomitant decrease in the exosomal markers on IFN-I
treatment was also observed after an additional purification step
by ultracentrifugation in a sucrose gradient (Supplementary
Fig. 1B). Interestingly, the few EVs secreted by IFN-treated cells
were recovered in different fractions than the EVs from non-
treated cells, suggesting that they might be of different nature.
To further investigate the function of ISGylation in controlling
EVs secretion, we next overexpressed ISG15 and the machinery
responsible for ISGylation (E1, E2 and E3) in HEK293 cells,
which mimics the activation of the ISG15 pathway
(Supplementary Fig. 1A)24,28 without activating other pathways
induced by IFN-I treatment. ISGylation induction inhibited the
secretion of EVs containing CD63, TSG101 and CD81 (Fig. 1b).
To dissect whether the inhibition in exosomal markers secretion
was due to ISG15 overexpression itself or to increased ISG15
conjugation to proteins, we overexpressed the ISGylation
machinery together with an ISG15 mutated at the carboxy-
terminal (ISG15MUT), thus disabling protein conjugation. Cells
overexpressing ISG15MUT showed higher levels of exosomal
markers in comparison with ISG15WT (Fig. 1c), demonstrating
that ISG15 conjugation to proteins, but not free ISG15, is
required for the inhibition of exosomal markers secretion.
Nanoparticle tracking analysis (NTA) showed a decrease in the
number of particles secreted on ISG15WT overexpression in
comparison with ISG15MUT-expressing cells (Supplementary
Fig. 1C), indicating that ISGylation is not causing a mere decrease
in the sorting of exosomal markers in EVs, but an actual decrease
in exosome secretion. However, NTA did not reveal any
significant decrease in the secretion of nanoparticles on IFN-I
treatment (Supplementary Fig. 1D).
To study the role of ISG15 in exosome secretion in a more
physiological context, we analysed the secretion of exosomes by
primary cells from wild-type (WT), ISG15 knockout (ISG15KO)42
and USP18C61A mice, which have the ISG15 de-conjugating
enzyme USP18 enzymatically inactive and thus show higher levels
of protein ISGylation33. Consistent with the inhibition of
exosome secretion induced by ISGylation, IFN-I treatment
decreased exosome secretion in primary bone marrow-derived
macrophages (BMDMs) from WT mice but not in ISG15-
deficient macrophages (Fig. 1d). Furthermore, BMDMs from
USP18C61A mice secrete less exosomes than either WT or
ISG15KO mice on ISGylation induction by IFN-I, supporting the
role of ISG15 protein conjugation in the regulation of exosome
secretion. Similar results were also obtained with primary
T lymphoblasts (Supplementary Fig. 1E). To assess the role of
ISGylation in vivo, poly (I:C) was injected intraperitoneally
into WT, ISG15KO and USP18C61A mice, to induce ISG15
expression43, and exosomes from blood serum analysed.
Interestingly, there were less exosomes in serum from poly
(I:C)-injected WT than ISG15KO mice, and even less exosomes in
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serum from injected USP18C61A mice (Fig. 1e), demonstrating
the role of ISGylation in the inhibition of exosome secretion
in vivo. Overall, our gain- and loss-of-function experiments
strongly support the role of ISGylation in the regulation of
exosome secretion in vitro and in vivo.
ISGylation decreases MVB numbers. To investigate the
mechanisms by which ISGylation controls exosome secretion,
MVBs were studied. Hepatocyte growth factor-regulated tyrosine
kinase substrate (HRS) is involved in MVB formation and exo-
some secretion17,44, and it has been previously used as a marker
of MVBs, being present in intermediates between early and late
MVBs positive for TSG101 and LBPA44,45. ISGylation induction
resulted in a more perinuclear and clustered localization of HRS,
as shown by the increase in the size of HRSþ structures (Fig. 2a),
and decreased the number of HRSþ spots per cell
(Supplementary Fig. 2A). Similar results were obtained with the
MVB marker CD63 (Fig. 2a and Supplementary Fig. 2A), whereas
the early endosome (EE) marker EEA1 did not show any
apparent alteration (Supplementary Fig. 2B). Electron microscopy
analyses revealed significant reduced MVBs numbers and density
on ISGylation induction (Fig. 2b). In accordance, IFN-I treatment
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Figure 1 | ISGylation inhibits exosome secretion. (a) Western blot analysis of EVs purified by serial ultracentrifugation from cell culture supernatants from
equal numbers of Jurkat T cells untreated (Cont) or treated with 1,000 U ml 1 IFN-I for 16 h. Cells and EVs (Exo) were blotted for the exosomal markers
CD63, TSG101, Flotillin and CD81, and for the endoplasmic reticulum marker Calnexin. Right graph: quantification of exosomal protein levels in the EVs
obtained from IFN-I-treated and untreated cells in three independent experiments. (b) Western blot analysis of the EVs obtained from equal numbers of
untransfected HEK293 cells (Cont) or co-transfected with ISG15 and the ISGylation machinery; E1, E2, E3 ligases (ISG15). Cells and EVs (Exo) were blotted
for CD63, TSG101, CD81 and Calnexin. Right graph: quantification of exosomal protein levels in the EVs obtained from untransfected HEK293 cells or co-
transfected with ISG15 and the ISGylation machinery in three independent experiments. (c) Western blot analysis of the EVs obtained from equal numbers
of HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and the functional (ISG15WT) or mutated ISG15 (ISG15MUT). Cells and
EVs (Exo) were blotted for CD63, CD81 and Calnexin. Right graph: quantification of exosomal protein levels in four independent experiments. (d) Western
blot analysis of the EVs obtained from equal numbers of WT, ISG15KO and USP18C61A BMDMs treated 16 h with IFN-I or left untreated. Cells and EVs were
blotted for TSG101 and quantification of exosomal protein levels of IFN-I-treated and -untreated cells is shown for three independent experiments.
(e) Western blot analysis of the EVs obtained in blood serum from poly(I:C)-injected WT, ISG15KO and USP18C61A mice. EVs were isolated from 250ml of
serum and blotted for TSG101. Right graphs: quantification of exosomal TSG101 protein levels of three mice per genotype; t-test *P-valueo0.05,
**P-valueo0.001 and ***P-valueo0.0001.
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Figure 2 | ISGylation decreases MVB numbers. (a) Confocal microscopy analysis of the endosome markers HRS (red) and CD63 (green) in
non-transfected HEK293 cells or HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and the functional (ISG15WT) or mutated
ISG15 (ISG15MUT). Scale bar, 10mm. Right graph: quantification of HRSþ and CD63þ average particle size per cell (n¼ 20). Each dot represents the
average particle size from individual cells and mean is indicated in red lines. (b) Electron microscopy images showing representative fields with MVBs
(red arrows) and lysosomes/autophagosomes (blue arrows) in HEK293 transfected as in a. Right graph: quantification of MVB numbers in more than
25 fields per condition. Each dot represents the number of MVBs per section and mean is indicated in red lines. Scale bar (insets), 500 nm. (c) Confocal
microscopy analysis of HRS in WT or ISG15KO BMDMs left untreated or treated with 1,000 U ml 1 IFN for 16 h. Scale bar, 10mm. Right graph: quantification
of the number of HRSþ particles per cell. Each dot represents the number of HRSþ particles from individual cells and mean is indicated in red lines
(n¼ 28). (d) Electron microscopy images showing MVBs (red arrows) in WT or ISG15KO BMDMs treated with 1,000 U ml 1 IFN for 16 h. Upper graph,
quantification of MVB numbers in 20 fields per condition. Each dot represents the number of MVBs per section and mean is indicated in red lines. Lower
graph, quantification of ILV numbers per MVB. Each dot represents the number of ILVs per MVB and mean is indicated in red lines (nZ24). Scale bar
(insets), 500 nm. (e) Confocal microscopy analysis of CD63 (red) in Rab5-Q79L-GFPþ endosomes (green). HEK293 cells were transfected with
Rab5-Q79L-GFP and treated 16 h with 1,000 U ml 1 IFN or left untreated. (f) Confocal microscopy analysis of CD63 (red) in Rab5-Q79L-GFPþ endosomes
(green). HEK293 cells were co-transfected with Rab5-Q79L-GFP mutant, the ISGylation machinery and ISG15WT or ISG15MUT. Images from e,f: Scale bar,
10mm. Right graphs: each dot represents the percentage of CD63-filled endosomes per individual cell and mean is indicated in red lines; t-test;
NS: P-value40.05 and ***P-valueo0.0001.
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macrophages (Fig. 2c), and MVBs were more abundant in
ISG15KO macrophages than in their WT counterparts on IFN-I
treatment (Fig. 2d), overall suggesting a role for ISG15 in
regulating MVB numbers.
To ascertain whether ISGylation decreases MVB numbers
by affecting MVB formation, we transfected HEK293 cells with
the constitutively active Rab5-Q79L-GFP mutant, which forms
large endosomes with a mixed morphology between EE and
MVBs, which facilitates the study of the first steps in MVB
biogenesis46,47. ISGylation induction by either IFN-I or ISG15
overexpression did not affect the sorting of the exosomal protein
CD63 into Rab5-Q79L-GFP endosomes (Fig. 2e,f). Furthermore,
quantitative electron microscopy analyses did not show any
significant differences in the number of ILVs per MVB on
ISGylation induction (Supplementary Fig. 2C,D). To rule out any
possible side effect derived from the uneven distribution of small
ILVs within enlarged MVBs48, ILV numbers were also quantified
in the absence of Rab5-Q79L-GFP overexpression. Accordingly,
macrophages from WT and ISG15KO mice also showed similar
levels of ILVs per MVB on ISGylation induction by IFN (Fig. 2d).
Altogether, these data support that ISGylation does not impair
the formation of ILVs, suggesting that it is mainly affecting later
stages on the MVB pathway.
ISGylation induces protein aggregation and degradation. We
then sought to understand how ISGylation regulates MVB
numbers and exosome secretion. For this, we used ISG15 fusion
proteins as models of protein ISGylation, as previously described
for other posttranslational modifications such as ubiquitin or
other UBLs49–51. Although fusion proteins are not exactly the
same than endogenous ISGylation in lysines, in our ISG15 fusion
proteins the C-terminal glycine of ISG15 is fused to the NH2
group of the target protein in the N-terminal amino acid through
a peptidic bond, which is chemically analogue to the isopeptidic
bond formed between the endogenous ISG15 and the NH2 group
of a target protein lysine.
Confocal analysis showed partial co-localization of ISG15-GFP
fusion protein with the MVB marker HRS and with the
aggresome marker p62 (ref. 52 and Fig. 3a,b), whereas no
co-localization was detected with the EE marker EEA1
(Supplementary Fig. 3A). Notably, ISGylation increased the
co-localization of HRS with the lysosome marker LAMP1
(Fig. 3c), although neither LAMP1 content nor localization were
affected (Supplementary Fig. 3B).
Despite its co-localization with MVB markers, green
fluorescent protein (GFP) was not found in exosomes when
fused to ISG15 (Fig. 3d) but rather promoted its accumulation
in detergent-insoluble cell fractions (Fig. 3e), indicating that
ISGylation promotes protein aggregation. Western blot analysis
of cycloheximide-treated cells showed that when fused to ISG15,
GFP is degraded faster than GFP alone or when fused to the
ubiquitin-like modifier SUMO2, and that this degradation is
delayed by the lysosome inhibitor Bafilomycin A1 but not by the
proteasome inhibitor MG132 (Fig. 3f and Supplementary
Fig. 3C–E), thus indicating that ISGylation of proteins promotes
their degradation through the lysosome.
Inhibition of MVB–lysosome fusion rescues exosome secretion.
To assess whether ISGylation inhibits exosome secretion by
inducing MVB lysosomal degradation, we studied whether
inhibition of MVB fusion with lysosomes could recover exosome
secretion. Bafilomycin A1 is a proton pump inhibitor that
increases the pH of lysosomes and inhibits trafficking between
MVB and lysosomes53,54. Bafilomycin A1 treatment recovered
exosome secretion in HEK293 cells in which ISGylation was
induced by ISG15 overexpression (Fig. 4a), whereas it did not
increase exosome secretion in control cells (Supplementary
Fig. 4A), suggesting that ISGylation inhibits exosome secretion
by re-routing MVB to lysosomes but is not impairing MVB
biogenesis. This is also supported by the detection of ISGylated
proteins in exosomes on secretion recovery (Supplementary
Fig. 4B). Exosome secretion was also recovered despite ISGylation
induction by IFN-I in Jurkat T cells when treated with
Bafilomycin A1 (Supplementary Fig. 4C).
To avoid unspecific effects derived from the use of the
inhibitor, we also studied exosome recovery on Rab7T22N
dominant-negative mutant expression, which inhibits both
endosome–lysosome and autophagosome–lysosome fusion55–58.
Rab7T22N expression rescued exosome secretion in HEK293 cells
despite ISGylation induction by ISG15 overexpression (Fig. 4b),
whereas it did not increase exosome secretion in control cells
(Supplementary Fig. 4D), supporting that the ISGylation-induced
inhibition of exosome secretion is mediated by MVB fusion and
degradation by the lysosome.
Fusion of MVBs with autophagosomes on induction of
autophagy by rapamycin has been reported56. Interestingly, the
secretion of exosomes on ISGylation induction was also recovered
on silencing of the autophagy mediator ATG5 (Fig. 4c),
indicating that autophagy probably contributes to the decreased
exosome release induced by ISGylation. Accordingly, IFN-I
treatment promoted the localization of the autophagy mediator
LC3 in more acidic compartments, presumably lysosomes,
supported by the loss of GFP fluorescent signal in mRFP-GFP-
LC3 tandem reporter (Fig. 4d). Notably, ISGylation induction by
IFN-I treatment or ISG15 overexpression did not induce
general autophagy, as evidenced by unaltered levels of p62
and other autophagy markers (Supplementary Fig. 4E,F),
indicating that ISGylation promotes selective autophagy and
degradation of MVB without inducing a global autophagy
response.
ISG15 impairs exosome secretion by modifying TSG101. To
elucidate the molecular mechanism by which ISGylation regulates
exosome secretion, we focused on TSG101, a component of the
ESCRT machinery involved in exosome biogenesis that has been
shown to be ISGylated and to regulate the secretion of virus40.
To confirm TSG101 ISGylation, we overexpressed the ISGylation
machinery together with WT or mutated ISG15 fused to the
V5 tag and performed V5 immunoprecipitation. Western blot
analysis of TSG101 in V5-ISG15 but not in control or
V5-ISG15MUT immunoprecipitates confirmed endogenous
TSG101 ISGylation (Fig. 5a). Moreover, ISGylation induction
by ISG15 overexpression induced endogenous TSG101
aggregation and accumulation in insoluble fractions (Fig. 5b).
To address whether ISGylation of TSG101 is sufficient to inhibit
exosome secretion, we generated a TSG101-GFP plasmid that
mimics TSG101 ISGylation (referred as ISG15-TSG101-GG), in
which ISG15 terminal glycine is conjugated to TSG101
N-terminal through a peptide bound that can be cleaved by the
USP18 de-ISGylase (Supplementary Fig. 5A). Consequently,
both ISGylated and de-ISGylated TSG101-GFP are detected in
cells transfected with this plasmid (Fig. 5c). Interestingly,
ISGylated TSG101-GFP accumulated in insoluble fractions
and was degraded faster than de-ISGylated TSG101-GFP
(Fig. 5d,e), consistent with ISGylation promoting TSG101
protein aggregation and degradation. The expression of the
ISG15-TSG101-GG plasmid rescued exosome secretion in cells
targeted for endogenous TSG101 (Fig. 5f and Supplementary
Fig. 5B), probably due to the presence of a functional
de-ISGylated form of TSG101. To circumvent this, we
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generated a non-de-ISGylable TSG101 mutant by changing ISG15
terminal glycines into alanines (ISG15-TSG101-AA), thus
preventing TSG101 de-ISGylation (Fig. 5c). In cells devoid of
endogenous TSG101, overexpression of the non-de-ISGylable
TSG101 mutant did not restore the secretion of exosomes (Fig. 5g
and Supplementary Fig. 5C), supporting that ISG15 conjugation
to the ESCRT component TSG101 is sufficient to inhibit the
secretion of exosomes.
Discussion
Cells secrete a variety of EVs including shedding vesicles, coming
from the direct evagination of the plasma membrane, and
exosomes, coming from endosomal compartments called MVBs.
The membrane of MVB invaginates to form ILVs, which are
secreted to the extracellular environment on MVB fusion with the
plasma membrane5. MVBs can also fuse with the lysosomal
compartment for the degradation of their content. There is
evidence that different types of MVB co-exist in cells59, although
the differences in their composition and the mechanisms that
control their biogenesis and final fusion with the lysosome or
plasma membrane are not well understood10. In addition, on
specific stimuli such as starvation or rapamycin treatment, MVBs
can be re-routed to promote their fusion with the lysosomal
compartment and thus avoid their fusion with the plasma
membrane and the concomitant secretion of exosomes56
demonstrating that the final fate of MVBs is not immutable but
can change under specific conditions60.
The role of the ESCRT complex in the sorting of ubiquitinated
proteins into ILVs for their degradation in the lysosome is well
known61 and some of the ESCRT complex components are also
involved in the secretion of exosomes and other EVs12,17,
although their precise role in the biogenesis of the different
types of EVs is not known. Other ubiquitin-like modifiers have
been shown to control the composition of EVs, for example,
SUMOylation of hnRNPA2B1 promotes the sorting of specific
microRNAs into exosomes18, and also controls the sorting of
a-synuclein into EVs19. Here we identify the ubiquitin-like
modifier ISG15 as a novel regulator of the exosome pathway.
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Figure 3 | ISG15 conjugation induces protein aggregation and degradation by lysosomes. (a) Confocal co-localization analysis of ISG15-GFP (green) and
the MVB marker HRS (red). Right graphs: fluorescence intensity profiles of ISG15-GFP (green) and HRS (red) in the regions delineated by a white line.
Nuclei were stained with DAPI. Scale bar, 10mm. (b) Confocal co-localization analysis of ISG15-GFP (green) and p62 (red). Right graphs represent
fluorescence intensity profiles of ISG15-GFP (green) and p62 (red) of the regions delineated by a white line. Nuclei were stained with DAPI. Scale bar,
10mm. (c) Confocal microscopy analysis of HRS (green) and LAMP1 (red) co-localization in HEK293 cells co-transfected with ISGylation machinery and
functional (ISG15WT) or mutated ISG15 (ISG15MUT). Nuclei were stained with DAPI. Scale bar, 10mm. Co-localization area per cell was quantified by
ImageJ (n¼ 16). Each dot represents the percentage of co-localization area per cell surface and mean is indicated in red lines. (d) Western blot analysis of
exogenous ISG15 in HEK293 cells transfected with ISG15-GFP. Cells and EVs (EXO) were blotted for GFP and CD81. (e) Western blot analysis of ISG15-GFP
and GFP in 0.5% NP-40 soluble and insoluble cell fractions in HEK293 transfected with GFP or ISG15-GFP. Right graph: quantification of GFP and ISG15-GFP
in the insoluble fraction respect to the soluble fraction in three independent experiments. (f) Western blot analysis of GFP and ISG15-GFP degradation
kinetics in HEK293 cells transfected with GFP or ISG15-GFP and treated with cycloheximide to inhibit protein synthesis during the indicated times. Where
specified, the medium was supplemented with the lysosome inhibitor Bafilomycin A1 (BAF) or the proteasome inhibitor MG132. A representative blot from
two independent experiments is shown. Data from c,e: t-test *P-valueo0.05 and ***P-valueo0.0001.
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overexpression or IFN-I decreases the secretion of exosomal
markers. Importantly, experiments with the non-conjugable
ISG15MUT and with primary cells from mice with defective
function of the specific ISG15 de-ISGylase USP18 demonstrated
that this effect is mediated by ISG15 conjugation to proteins and
not by free ISG15. ISGylation induction by ISG15 overexpression
induces a decrease in microparticle secretion, indicating that
ISGylation is not merely decreasing the sorting of certain
exosomal markers into ILVs but is actually decreasing exosome
secretion. However, ISGylation induction by IFN-I does not
induce a significant decrease in the number of secreted
microparticles. This could be due to the induction of the
secretion of other types of EVs by IFN-I and this is in
agreement with previous reports showing that IFN-I can
promote the secretion of EVs loaded with antiviral components
that are transferred to other cells62. In fact, on ultracentrifugation
in sucrose gradients, the few EVs secreted by IFN-treated cells are
recovered in different fractions than the EVs from non-treated
cells, suggesting that they might have a different nature.
Alternatively, the absence of effect of IFN on global particle
secretion may indicate that only the EVs derived from MVBs are
affected.
We also show that ISGylation decreases the numbers of MVBs,
but does not prevent the formation of ILVs. The secretion of
exosomes is recovered when the fusion of MVB with lysosomes or
autophagosomes is inhibited, indicating that the observed
inhibition of exosome secretion is mainly mediated by the
induction of MVB degradation by the lysosome. In accordance,
we show that ISGylation promotes the aggregation and
degradation of proteins by the lysosome, and this is in agreement
with previous reports in which ISG15-linked proteins associated
with the proteins p62 and HDAC-6 involved in the autophagic
process52. We have observed that ISGylation decreases the
number of HRSþ structures without preventing the formation
of ILVs, possibly reflecting an accelerated degradation of
endosomes. In addition, ISGylation increases the co-localization
of the lysosome marker LAMP-1 with HRS, which is usually
absent from LAMP-1-positive structures44. Whether ISGylation
of MVB proteins induces the rapid fusion of MVB with lysosomes
in an earlier stage of maturation, or whether it directly impairs
HRS dissociation from endosomal membranes is not known.
A number of ISG15 target proteins are typically present in
exosomes and MVBs41, including several components of the
ESCRT complex such as TSG101, CHMP2A, CHMP4B and
CHMP6 (refs 40,63,64). It is therefore conceivable that ISG15 is
recruited to MVB by conjugating endosomal proteins. There, it
may promote protein aggregation and enhance MVB degradation
by the autophagosome–lysosome compartment, thus preventing
their fusion with the plasma membrane and the secretion of
exosomes (Fig. 6). We have validated the ISGylation of TSG101,
which has been previously shown to control the secretion of viral
particles40, and we show that TSG101 ISGylation is sufficient to
impair exosome secretion. However, we cannot rule out the
possibility that other endosomal proteins are being ISGylated and
also contribute to the inhibition of exosome secretion induced by
ISG15. TSG101 depletion has been previously shown to inhibit
MVB formation65 or to modify the size of MVBs and/or the





















































































































































































Figure 4 | Inhibition of lysosome function upon ISGylation induction rescues exosome secretion. (a) Western blot analysis of exosome secretion in
untransfected HEK293 cells and HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and ISG15, and treated with Bafilomycin A1
(BAF), when indicated. Cells and EVs (Exo) were blotted for CD63 and CD81. Right graph: quantification of exosomal protein levels in three independent
experiments. (b) Western blot analysis of exosome secretion in HEK293 cells transfected with GFP or co-transfected with plasmids encoding ISG15 and the
ISGylation machinery, and when indicated, with the Rab7T22N dominant-negative mutant. Cells and EVs were blotted for CD63 and CD81. Right graph:
quantification of exosomal protein levels in three independent experiments. (c) Western blot analysis of exosome secretion in HEK293 cells transfected
with control small interfering RNAs (siRNAs) or siRNAs targeting ATG5. After 48 h, cells were re-transfected with siRNAs together with plasmids encoding
ISG15 and ISGylation machinery. Cells and EVs (Exo) were blotted for CD63 and CD81. Right: quantification of exosomal protein levels in three or four
independent experiments. (d) Confocal analysis of LC3 localization into acidic compartments in HEK293 cells transfected with LC3-RFP-GFP tandem
plasmid and treated 16 h with IFN-I where indicated. Nuclei were stained with DAPI. Scale bar, 10mm. Images were processed by ImageJ and the number of
RFPþ and RFPþGFPþ dots quantified. Each dot represents the percentage of RFPþGFPþ dots per individual cell and mean is indicated in red lines; t-test;
***P-valueo0.001. Data a,b,c: analysis of variance; *P-valueo0.05, **P-valueo0.001 and ***P-valueo0.0001.
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between depletion and ISGylation of TSG101. ISG15 may be
directed to endosomes in a later stage of their maturation and
here modify MVB proteins such as TSG101, and promote their
aggregation and subsequent degradation by the lysosome without
impairing ILV biogenesis. However, we could not completely rule
out any effect of ISGylation on MVB biogenesis.
ISGylation has been previously shown to exert an antiviral
activity by blocking the exit of viral particles36,40,64,66. The
ISGylation of multiple MVB proteins and the consequent
inhibition of exosome secretion induced by IFN-I would
prevent the spreading of viruses that exploit the MVB
pathway for their way out the cell. In addition, exosomes play
important roles in cell-to-cell communication during the immune
response, tumour progression, neuron survival and many other
contexts1,3,4,67. Therefore, ISGylation induction by different
stimuli such as viral infection, IFN, ischaemia68 or ageing69 can
be an important mechanism to regulate exosome-mediated
communication in many different situations.
Methods
Cell culture. The human Jurkat-derived T-cell line J77cl20 (TCR Val. 2 Vb8) was
cultured in RPMI (Sigma) containing 10% fetal bovine serum (FBS; Invitrogen).
The HEK293T cell line was cultured in DMEM medium (Sigma) containing 10%
FBS (Invitrogen).
Mouse primary macrophages (BMDMs) were obtained from the bone marrow
of C57BL/6 WT, ISG15 knockout42 and USP18C61A mice33 (kindly provided by
K. Knobeloch, Freiburg University, Germany). Cells were cultured RPMI-1640
supplemented with macrophage colony-stimulating factor (30% mycoplasma-free
L929 cell supernatant, NCBI Biosample accession number SAMN00155972) for
6 days, to induce cell differentiation.
Mouse primary T lymphocytes were obtained from cell suspensions prepared
from spleens and peripheral lymph nodes of C57BL/6 WT, ISG15KO USP18C61A
mice. Cells were cultured for 36–48 h in RPMI with 2 mg ml 1 concanavalin A
(Sigma) and subsequently 50 U ml 1 human recombinant IL-2 (Glaxo) was added
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Figure 5 | ISG15 impairs exosome secretion by modifying TSG101. (a) Western blot analysis of TSG101 immunoprecipitation in HEK293 cells
non-transfected or HEK293 cells co-transfected with plasmids encoding the ISGylation machinery and functional (ISG15WT) or mutated ISG15
(ISG15MUT). Total lysates and V5 immunoprecipitates were blotted for TSG101. (b) Western blot analysis of 0.5% NP-40 soluble and insoluble fractions
from non-transfected HEK293 cells (Cont) or cells transfected with ISG15 and ISGylation machinery (ISG15). Soluble and insoluble fractions were blotted
for TSG101 and GAPDH. Right graph: quantification of TSG101 protein levels in insoluble fractions in three independent experiments. (c) Western blot
analysis of TSG101-GFP ISGylation in HEK293 cells transfected with ISG15-TSG101-GFP-GG or with the non-de-ISGylable mutant ISG15-TSG101-GFP-AA.
Cell lysates were blotted for GFP. Right graph: quantification of ISG15-TSG101-GFP/TSG101-GFP ratio in three independent experiments. (d) Western blot
analysis of ISG15-TSG101-GFP and TSG101-GFP subcellular distribution in HEK293 cells transfected with ISG15-TSG101-GFP-GG. Fractions corresponding
to cytosol (F1), membranes (F2), nucleus (F3) and insoluble aggregates (F4) were extracted and blotted for GFP and CD81. A lower exposition of the same
blot is shown for F4. (e) Western blot analysis of ISG15-TSG101-GFP and TSG101-GFP degradation kinetics in HEK293 cells transfected with ISG15-TSG101-
GFP-GG and treated with cycloheximide during the indicated times. Cell lysates are blotted for GFP. (f) Western blot analysis of HEK293 cells transfected
with control small interfering RNAs (siRNAs) or siRNAs targeting TSG101. When indicated, cells were co-transfected with ISG15-TSG101-GFP-GG. Cells
and EVs (EXO) were blotted for CD63 and CD81. Lower gel shows cell lysates blotted for TSG101 to check TSG101 silencing and exogenous overexpression.
Lower graph: quantification of exosomal protein levels in three independent experiments. (g) Western blot analysis of HEK293 cells transfected with
control siRNAs or siRNAs targeting TSG101. When indicated, cells were co-transfected with the non-de-ISGylable mutant ISG15-TSG101-GFP-AA. Cells and
EVs (EXO) were blotted for CD63 and CD81. Lower gel shows cell lysates blotted for TSG101 to check TSG101 silencing and exogenous overexpression.
Lower graph: quantification of exosomal protein levels in three independent experiments. Data b,c: t-test; NS: P-value40.05 and *P-valueo0.05. Data f,g:
analysis of variance; NS: P-value40.05 and *P-valueo0.05.
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to the medium every 2 days for at least 4–6 days, to obtain differentiated
T lymphoblasts.
Exosome purification. Cells were cultured in medium supplemented with 10%
exosome-depleted FBS (bovine exosomes were removed by overnight centrifuga-
tion at 100,000 g). Supernatant fractions were collected from 16 to 20 h cell culture
supernatants and exosomes were obtained by serial centrifugation as follows. Cells
were pelleted (320 g for 10 min) and the supernatant was centrifuged at 2,000 g
for 15 min, to discard debris and dead cells. The supernatant was collected and
ultracentrifuged at 10,000 g for 30 min at 4 C (Beckman Coulter Optima L-100 XP,
Beckman Coulter) and exosomes were pelleted by ultracentrifugation at 100,000 g
for 70 min at 4 C. The exosome pellet was washed in PBS and collected by
ultracentrifugation at 100,000 g for 70 min (Beckman Coulter Optima L-100 XP,
Beckman Coulter).
Nanoparticle tracking analysis. Exosome numbers and size distribution were
determined by measuring the rate of Brownian motion using a NanoSight LM10
system, which is equipped with fast video capture and particle-tracking software
(NanoSight, Amesbury, UK). Samples were diluted before analysis to between
2 108 and 20 108 particles per ml, and the relative concentration was calculated
according to the dilution factor. Data analysis was performed with NTA 2.1
software (Nanosight). Samples were analysed using manual shutter and gain
adjustments, which resulted in shutter speeds of 15 or 30 ms, with camera gains
between 280 and 560. The detection threshold was kept above 2; blur: auto;
minimum expected particle size: 50 nm.
ISGylation induction by overexpression. HEK293 cells were co-transfected
with plasmids encoding human E1, E2 and E3 ligases (kindly provided by
A. Garcı́a-Sastre, Mount Sinai Hospital, NYC) together with plasmids encoding
WT or C-terminal mutated human ISG15 fused to the V5 tag. When indicated,
cells were co-transfected with the appropriate small interfering RNAs or with the
EGFP-Rab7A T22N plasmid (gift from Qing Zhong, Addgene plasmid 28048).
Cells were transfected using Lipofectamine 2000 (Invitrogen). Twenty-four hours
after transfection, cells were cultured in exosome-depleted medium for 20 h and
exosomes were isolated from supernatants as described above. When indicated,
cells were incubated overnight in exosome-depleted medium containing 20 nM
Bafilomycin A1 (Merck).
Exosome extraction from blood serum. WT, ISG15KO and USP18C61A mice
were treated with 5 mg g 1 body weight poly (I:C) (InvivoGen) intraperitoneally.
Blood samples were extracted from the heart 24 h after poly (I:C) injection and
allowed to clot 3 h at room temperature. Blood samples were kept 2 h at 4 C and
serum was obtained by centrifugation at 400 g, 10 min at 4 C. Cell debris were
removed by centrifugation at 3,000 g, 15 min at 4 C and serum samples were
stored at  20 C. Exosomes were extracted from serum as previously described70;
briefly, 125ml of Exoquick reagent were added to 250 ml of serum and incubated
overnight at 4 C. Samples were centrifuged at 1,500 g, 30 min and exosome pellets
resuspended in RIPA buffer.
Gene silencing. HEK293 cells were transfected using Lipofectamine 2000
(Invitrogen) with the following small interfering RNAs: control (scrambled), ATG5
and TSG101 (SIGMA). Twenty-four hours after transfection, cells were cultured in
exosome-depleted medium for 20 h and exosomes were isolated from supernatants
as described above.
Western blotting. Cells or exosomes were lysed in RIPA buffer (50 mM Tris-HCl
pH 8, 150 mM NaCl, 1% Triton X-100, 0.1% sodium deoxycholate and 0.1% SDS)
containing a protease inhibitor cocktail (Complete, Roche). Proteins were separated
on 10% acrylamide/bisacrylamide gels and transferred to a nitrocellulose
membrane. Membranes were incubated with primary antibodies (1:1,000) and
peroxidase-conjugated secondary antibodies (1:5,000), and proteins were visualized
with LAS-3000. The following antibodies were used: rabbit anti-human ISG15
(Proteintech, 15981-1-AP), mouse anti-human CD63 (Calbiochem, OP171), mouse
5A6 anti-human CD81 (Santa Cruz, sc-23962), mouse anti-human TSG101
(Abcam, GTX70255), mouse anti-GFP (Living colors, 632381), rabbit anti-p62
(Sigma, P0067), mouse DM1A anti-tubulin (Sigma, F2168), rabbit anti-Calnexin
(Abcam, ab10286), goat anti-mouse peroxidase (Thermo Scientific), goat
anti-rabbit peroxidase (Thermo Scientific) and donkey anti-goat peroxidase
(Thermo Scientific). Full immunoblots are provided in Supplementary Fig. 6.
Fluorescence confocal microscopy. For immunofluorescence assays, cells were
plated onto slides coated with fibronectin (20 mg ml 1), incubated for 16 h min,
fixed with 2% paraformaldehyde and stained with the indicated primary antibodies
(1:100) followed by secondary antibodies (1:500). When indicated, cells were
previously transfected with GFP-Rab5CA (Q79L) plasmid (gift from Sergio
Grinstein, Addgene plasmid 35140) or LC3-GFP-RFP tandem construct (gift from
Tamotsu Yoshimori, Addgene plasmid 21074). Samples were examined with a
Leica SP5 confocal microscope (Leica) fitted with a  63 objective and images were
processed and assembled using Leica software. The following antibodies were used:
anti-CD63 (clone Tea 3/18, generated in the laboratory), anti-HRS (Abcam,
ab72053), anti-EE1A (Santa Cruz, sc-6415), anti-LAMP1-647 (BioLegend, 328612),
anti-p62 (Sigma, P0067), goat anti-mouse-488 and goat anti-rabbit-RX (Life
Technologies). Images were processed and quantified using LAS-AF and ImageJ.
Cloning. ISG15-GFP plasmids were generated by excision of ISG15 from the
pCAGG plasmid with XhoI and EcoICRI restriction enzymes, followed by insertion
between the XhoI and AfeI sites of pAcGFP-N1. ISG15 stop codons were mutated
using the QuickChange Site-Directed Mutagenesis kit (Agilent). ISG15-TSG101-
GFP was obtained by inserting TSG101 into ISG15-GFP plasmid with XhoI and
BamHI restriction enzymes. Non-de-ISGylable mutant ISG15-TSG101-GFP-AA
was obtained by mutated terminal glycines into alanines using the QuickChange
Site-Directed Mutagenesis kit (Agilent). Ubiquitin-GFP expressing plasmid was
obtained from Addgene (gift from Nico Dantuma, Addgene plasmid 11928).
Protein aggregation. HEK293 cells were transfected with GFP or ISG15-GFP
plasmids using Lipofectamine 2000 (Invitrogen) and 48 h later lysed in lysis buffer
(10 mM Tris-HCl pH 8, 100 mM NaCl, 1 mM EDTA, 0.5% NP40 and 50 mM
iodoacetamide) supplemented with protease inhibitor cocktail (Complete, Roche).
Cells were centrifuged for 5 min a 13,000 g, and the supernatant (S1) and pellet (P1)
were saved. P1 was resuspended in lysis buffer containing 2% SDS, sonicated and
centrifuged at 16,000 g for 10 min. The pellet (P2) was resupended in lysis buffer
containing 2% SDS and sonicated. S1 and P2 were loaded on a poly-acrylamide gel
and blotted for GFP. Subcellular fractionation was performed with ProteoExctarct
Subcellular Proteome Extraction kit (Calbiochem).
Protein degradation. HEK293 cells were cultured in six-well-plates and
transfected with GFP or ISG15-GFP using Lipofectamine 2000 (Invitrogen).
Cells were treated with 40 mg ml 1 cycloheximide (Sigma) to inhibit protein
synthesis and were lysed at the indicated time points. When indicated, the medium
contained 20 nM Bafilomycin A1 (Merk) or 40 mM MG132 (Sigma).
Immunoprecipitation. 1 107 HEK293 cells per condition were lysed (25 mM
Tris pH 8, 150 mM NaCl, 2 mM MgCl2, 0.5% NP-40 and protease inhibitors) and
incubated for pre-clearing with pre-washed Protein G Dynabeads (Invitrogen; 50 ml
per condition; 1 h, 4 C). Fifty microlitres of Dynabeads per condition were washed
twice in 0.01% Tween PBS and resuspended in 200ml of 0.01% Tween PBS
containing 5 mg mouse anti-V5 antibody (Life Technologies) per condition and
incubated 1 h at 4 C. Pre-cleared lysates were incubated with antibody-conjugated
Dynabeads (1.5 h, 4 C). Antibody-conjugated Dynabeads were washed six times
with lysis buffer and transferred to clean tubes. Protein loading buffer was added,
samples were boiled at 95 C for 5 min and processed for immunoblotting.
Electron microscopy and MVB quantification. Cells cultured on dishes were
washed in PBS and fixed for 1 h in 2.5% glutaraldehyde in 0.1 M phosphate buffer
at room temperature. Then, cells were slowly and gently scrapped and pelleted in








Figure 6 | Proposed model for the role of ISGylation in the regulation
of exosome secretion. IFN-I induces ISG15 expression and conjugation
to MVB proteins such as TSG101. ISGylation of MVB proteins promotes
MVB fusion with lysosomes and degradation, thus inhibiting exosome
secretion.
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OsO4 for 90 min at 4 C. Then, samples were dehydrated, embedded in Spurr and
sectioned using Leica ultramicrotome (Leica Microsystems). Ultrathin sections
(50–70 nm) were stained with 2% uranyl acetate for 10 min and with a
lead-staining solution for 5 min and observed using a transmission electron
microscope, JEOL JEM-1010 fitted with a Gatan Orius SC1000 (model 832) digital
camera.
For the calibration of images, quantification and analysis ImageJ was used.
MVBs were identified and counted by morphology, having only discrete ILVs.
Lysosomes contain multilamellar profiles. At least 20 MVBs were analysed per
experiment from separate cells. Data were analysed from duplicate or triplicate
separate experiments and two to four grids were used for each condition. The
minimum number of cells scored for each condition was 20. Box scatter plots were
generated using Prism GraphPad software and statistical tests were performed in
Microsoft Excel. Data are means±s.d. and ***P-valueo0.0001.
Data availability. The data that support the conclusions of this study are available
from the corresponding author upon request.
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